Publications by authors named "F Aubin"
CAR-T cell therapy : recent updates and challenges in autoimmune diseases.
J Allergy Clin Immunol
December 2024
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies, demonstrating significant clinical efficacy and leading to FDA approval of several CAR-T cell-based products. This success has prompted exploration of CAR-T cell therapy in other disease areas, including autoimmune diseases (AIDs). CAR-T cells targeting B cells have been shown to provide clinical and biological improvements in patients with refractory AIDs.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of continuing immune checkpoint inhibition (ICI) treatment in patients with metastatic melanoma who experience disease progression, using data from 120 patients.
- It finds that patients who continued ICI treatment had a median overall survival (OS) of 4.2 months, significantly longer than the 1.3 months for those who stopped treatment after progression.
- Despite the survival benefits, the study noted increased hospitalizations and treatments at the end of life in patients continuing ICI, highlighting the need for balanced palliative care.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are a crucial treatment for various cancers, but grade≥3 immune-related adverse effects (irAEs) are not well studied; this research aimed to evaluate their incidence and characteristics.
- The study reviewed patients with advanced melanoma, lung cancer, or renal cancer who experienced severe irAEs while undergoing ICI therapy from 2016-2021, revealing a grade≥3 irAE incidence of 11.7%.
- The majority of severe adverse effects were hepatobiliary, gastrointestinal, musculoskeletal, and respiratory, typically occurring around 6 months into treatment, with a significant percentage leading to hospitalization; however, a majority of patients recovered without lasting issues.
Article Synopsis
- Rituximab (RTX) is a key treatment for various autoimmune and chronic inflammatory diseases but increases the risk of severe infections and lowers vaccine effectiveness due to its impact on B cell responses.
- During the COVID-19 pandemic, RTX-treated patients faced heightened disease severity, which led to delays or avoidance of RTX treatments to protect against SARS-CoV-2 infections.
- A study of thirteen patients showed that while some had positive T cell responses post-vaccination, those recently treated with RTX had significantly lower antibody responses, suggesting a need for caution in timing vaccinations relative to RTX infusions to optimize immune protection.